Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Berruti

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
Endocrine-Related Cancer|June 11, 2005
Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trialA Bottini, A Berruti, M P Brizzi, et al.
Lancet Regional Health. Americas|March 23, 2023
Lifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling studyShiying You, Reza Yaesoubi, Kyueun Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|March 12, 2004
Multimodal management of stages III-IVa malignant thymomaS Bretti, A Berruti, C Loddo, et al.
Journal of Endocrinological Investigation|June 24, 2023
Outcome of brain metastases from adrenocortical carcinoma: a pooled analysisA Turla, M Laganà, V Cremaschi, et al.
ESMO Open|March 10, 2022
Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinomaM Laganà, S Grisanti, R Ambrosini, et al.
Mycorrhiza|December 13, 2016
Arbuscular mycorrhizal fungal community differences among European long-term observatoriesM-L Bouffaud, C Bragalini, A Berruti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patientsA Bottini, A Berruti, A Bersiga, et al.
ESMO Open|October 26, 2024
Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upJ Hadoux, A Lamarca, E Grande, et al.
British Journal of Cancer|May 29, 2008
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastasesD Generali, A Dovio, M Tampellini, et al.
Anticancer Research|July 1, 1997
Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survivalA Berruti, P Zola, T Buniva, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
Endocrine-Related Cancer|June 11, 2005
Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trialA Bottini, A Berruti, M P Brizzi, et al.
Lancet Regional Health. Americas|March 23, 2023
Lifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling studyShiying You, Reza Yaesoubi, Kyueun Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|March 12, 2004
Multimodal management of stages III-IVa malignant thymomaS Bretti, A Berruti, C Loddo, et al.
Journal of Endocrinological Investigation|June 24, 2023
Outcome of brain metastases from adrenocortical carcinoma: a pooled analysisA Turla, M Laganà, V Cremaschi, et al.
ESMO Open|March 10, 2022
Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinomaM Laganà, S Grisanti, R Ambrosini, et al.
Mycorrhiza|December 13, 2016
Arbuscular mycorrhizal fungal community differences among European long-term observatoriesM-L Bouffaud, C Bragalini, A Berruti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patientsA Bottini, A Berruti, A Bersiga, et al.
ESMO Open|October 26, 2024
Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upJ Hadoux, A Lamarca, E Grande, et al.
British Journal of Cancer|May 29, 2008
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastasesD Generali, A Dovio, M Tampellini, et al.
Anticancer Research|July 1, 1997
Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survivalA Berruti, P Zola, T Buniva, et al.
Pageof 15